WO2006035195A1 - Preparation of opiate analgesics by reductive alkylation - Google Patents
Preparation of opiate analgesics by reductive alkylation Download PDFInfo
- Publication number
- WO2006035195A1 WO2006035195A1 PCT/GB2005/003547 GB2005003547W WO2006035195A1 WO 2006035195 A1 WO2006035195 A1 WO 2006035195A1 GB 2005003547 W GB2005003547 W GB 2005003547W WO 2006035195 A1 WO2006035195 A1 WO 2006035195A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reacted
- process according
- cyclopropyl
- Prior art date
Links
- 238000005932 reductive alkylation reaction Methods 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title description 8
- 229940035676 analgesics Drugs 0.000 title description 2
- 239000000730 antalgic agent Substances 0.000 title description 2
- 229940127240 opiate Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000003054 catalyst Substances 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 4
- 150000002576 ketones Chemical class 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 14
- 229910052727 yttrium Inorganic materials 0.000 claims description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 229910052721 tungsten Inorganic materials 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229960003086 naltrexone Drugs 0.000 description 10
- HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 description 7
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 5
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 5
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229960000805 nalbuphine Drugs 0.000 description 5
- STBZIDOIKQNFCQ-HSALFYBXSA-N oxilorphan Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CC1 STBZIDOIKQNFCQ-HSALFYBXSA-N 0.000 description 5
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 4
- 229950002494 diprenorphine Drugs 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000005002 aryl methyl group Chemical group 0.000 description 3
- 229960001736 buprenorphine Drugs 0.000 description 3
- 229960001113 butorphanol Drugs 0.000 description 3
- 229960005297 nalmefene Drugs 0.000 description 3
- 229960000858 naltrexone hydrochloride Drugs 0.000 description 3
- 229950011178 oxilorphan Drugs 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- -1 cyclic tertiary amine Chemical class 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 229910052987 metal hydride Inorganic materials 0.000 description 2
- 150000004681 metal hydrides Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- QMFVIJMHPXUVOL-RCGDHTHDSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-1,2,3,4,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 QMFVIJMHPXUVOL-RCGDHTHDSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ILJKKAIQFPEIBL-UHFFFAOYSA-N 2-cyclopropyl-2-hydroxyacetonitrile Chemical compound N#CC(O)C1CC1 ILJKKAIQFPEIBL-UHFFFAOYSA-N 0.000 description 1
- 0 C*[C@@](C1)[C@](C)C[C@]2(*)[C@@]1(C1)c3cc(*)ccc3CC11[C@@]2C1C* Chemical compound C*[C@@](C1)[C@](C)C[C@]2(*)[C@@]1(C1)c3cc(*)ccc3CC11[C@@]2C1C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- YOYLLRBMGQRFTN-IOMBULRVSA-N Norbuprenorphine Chemical compound C([C@@H](NCC1)[C@]23CC[C@]4([C@H](C3)[C@](C)(O)C(C)(C)C)OC)C3=CC=C(O)C5=C3[C@@]21[C@H]4O5 YOYLLRBMGQRFTN-IOMBULRVSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000004036 acetal group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- INVYSLWXPIEDIQ-UHFFFAOYSA-N cyclobutanecarbaldehyde Chemical compound O=CC1CCC1 INVYSLWXPIEDIQ-UHFFFAOYSA-N 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- NLBUEDSBXVNAPB-DFQSSKMNSA-N cyclorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC1CC1 NLBUEDSBXVNAPB-DFQSSKMNSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- UAIXRPCCYXNJMQ-HPRIMLMLSA-N nih-8805 Chemical compound Cl.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 UAIXRPCCYXNJMQ-HPRIMLMLSA-N 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a process for preparing naltrexone and structurally similar compounds such as nalbuphine, nalmefene, oxilorphan, butorphanol, diprenorphine and buprenorphine. All these compounds contain a cyclic tertiary amine.
- Naltrexone (1) is a narcotic analgesic:
- Nalbuphine (2) and nalmefene (3) are structurally similar compounds:
- Oxilorphan (4) and butorphanol (5) are also similar but there is no ether linkage between the so-called A and C rings:
- Diprenorphine (6) and buprenorphine (7) contain an ethyl bridge on the C ring:
- US 3,332,950 discloses methods for preparing this type of compound.
- Naltrexone is prepared from noroxymorphone in four steps.
- the method employs a hazardous metal hydride reagent in order to reduce the condensation product formed between a protected noroxymorphone and cyclopropylcarbonyl chloride.
- the method incorporates protection and deprotection steps. The inventors believe that this type of process afford yields of approximately 33% naltrexone starting from noroxymorphone hydrochloride.
- naltrexone is prepared by the direct coupling of cyclopropyhnethylbromide and noroxymorphone in dimethylformamide. The method employs high temperatures (7O 0 C) and prolonged reaction times (7 days) yet still only achieves a 60% theoretical yield.
- the present invention provides a process for preparing a compound of formula (A), (B) or (C):
- P is H, CH 3 or a hydroxyl protecting group
- X is O, a protected ketone, OH, a protected hydroxyl group or H
- Y is OH, a protected hydroxyl group or H
- W is C(CH 3 ) 2 OH, C(CH 3 )(C(CHj) 3 )OH or COCH 3
- Z is C 2 -C 10 alkyl or C 2 -C 10 arylalkyl
- 1 ⁇ is a single bond or a double bond;
- the method of the invention affords better yields than known processes and avoids the use of hazardous metal hydride reagents that are difficult to handle on a large scale. It does not require high temperatures or prolonged reaction times.
- P is H or CH 3 , preferably H.
- P is a hydroxyl protecting group such as an alkoxy, alkoxycarbonyl, aroxycarbonyl, arylmethyl, silyl ether, carbonate or sulphonate group and is preferably an alkoxy, alkoxycarbonyl, aroxycarbonyl or arylmethyl group.
- Suitable alkoxycarbonyl groups include propoxycarbonyl and ethoxycarbonyl.
- Suitable aroxycarbonyl groups include phenoxycarbonyl.
- Suitable arylmethyl groups include napthylmethyl and benzyl.
- X is preferably O (and therefore the bond between X and the C 6 ring is a double bond) or OH (and therefore the bond between X and the C 6 ring is a single bond).
- X may be a protected ketone group, e.g. an acetal group. If X is a protected hydroxyl group, the protecting group may be any of the hydroxyl protecting groups as listed above for P.
- Y is preferably OH. If Y is a protected hydroxyl group, the protecting group may be any of the hydroxyl protecting groups as listed above for P.
- Z is C 2 -C 10 alkyl or C 2 -C 10 arylalkyl, preferably C 2 -C 5 alkyl.
- alkyl includes straight chained, branched, cyclic and substituted alkyls, but preferably the alkyl group is unsubstituted.
- Z is cyclopropyl or cyclobutyl.
- bonds between the 6,7 carbons and the 7,8 carbons in the compounds of formula (A), (B), (D) and (E) may be double bonds or single bonds.
- the bond between the carbons of the ethyl bridge in the compounds of formula (C) and (F) may be a double bond or a single bond.
- Any double bonds in the compounds of formula (D), (E) or (F) may be hydrogenated in the presence of hydrogen and a reductive alkylation catalyst so compounds of formula (D), (E) and (F) with double bonds may provide compounds of formula (A), (B) and (C) with corresponding single bonds.
- the skilled person can vary the reaction conditions to favour hydrogenation of double bonds.
- a compound of formula (D) wherein P is H, X is O and Y is OH is reacted with a compound of formula (G) wherein Z is cyclopropyl.
- This provides a compound of formula (A) wherein P is H, X is O, Y is OH and Z is cyclopropyl. If the 6,7 and 7,8 bonds are single bonds, this compound is naltrexone.
- a compound of formula (D) wherein P is H, X is OH and Y is OH is reacted with a compound of formula (G) wherein Z is cyclobutyl.
- This provides a compound of formula (A) wherein P is H, X is OH, Y is OH and Z is cyclobutyl. If the 6,7 and 7,8 bonds are single bonds, this compound is nalbulphine.
- a compound of formula (E) wherein P is H, X is O and Y is OH or H is reacted with a compound of formula (G) wherein Z is cyclopropyl.
- This provides a compound of formula (B) wherein P is H, X is O, Y is OH or H and Z is cyclopropyl. If the 6,7 and 7,8 bonds are single bonds, these compounds are oxilorphan and cyclorphan.
- Z is cyclobutyl.
- P is H
- X is H
- Y is OH
- Z is cyclobutyl. If the 6,7 and 7,8 bonds are single bonds, this compound is butorphanol.
- a compound of formula (F) wherein P is H and W is C(CH 3 ) 2 OH is reacted with a compound of formula (G) wherein Z is cyclopropyl.
- a compound of formula (F) wherein P is H and W is C(CH 3 )(C(CHs) 3 )OH is reacted with a compound of formula
- W is C(CH 3 ⁇ C(CH 3 ) 3 )OH and Z is cyclopropyl. If the ethyl bridge has a single bond, this compound is buprenorphine.
- Suitable reductive alkylation catalysts are well known to the skilled person and include platinum group metal catalysts (e.g. platinum or palladium), nickel catalysts and mixtures of these catalysts.
- the amount of catalyst required is suitably 2 mole% or less, preferably about 0.2 mole%.
- the process is suitably carried out at room temperature or higher, preferably around 5O 0 C.
- Hydrogen is suitably supplied to the reaction at a pressure of 1 bar or greater, preferably about 3 bar.
- the solvent is suitably chosen from alcohols, ethers, amines, amides, alkanes, xylenes, chlorinated alkanes or mixtures - thereof.
- a preferred solvent is methanol.
- the process of the invention may take around 1 or more hours.
- Noroxymorphone alkaloid (20.Og, equivalent to 60.9mmol dry) was added to a mixture of iV-methylpyrrolidinone (60ml) and methanol (140ml). Cyclopropanecarboxaldehyde (5.3ml, 70.9mmol) and platinum on carbon catalyst were added and the mixture hydrogenated at 40psi and 50°C for 1 hour. Upon completion, the catalyst was filtered off and the reaction liquors diluted with chloroform (60ml) and washed with water (200ml). The aqueous layer was extracted with chloroform (2 x 60ml) and the combined organic layer washed with water (5 x 140ml).
- Nor-14-hydroxymorphinone (20.Og, equivalent to 62.1mmol dry), cyclopropane carboxaldehyde (5.3ml, 70.9mmol), 7V-methylpyrrolidinone (60ml) and methanol
- Cyclobutane carbonyl chloride (1.44ml, 25.2mmol) was hydrogenated for 2 hours in JV-methylpyrrolidinone (30ml) at 40 psi and room temperature in the presence of palladium on charcoal catalyst.
- the crude solution of cyclobutane carboxaldehyde was filtered through a bed of celite.
- noroxymorphone (2.78g, 7.96mmol) was added followed by platinum on carbon catalyst and the mixture hydrogenated at 50°C and 40psi. After 2 hours the catalyst was filtered off and sodium borohydride (3g) added portionwise.
- HPLC analysis of the crude reaction mixture and comparison against a known sample of nalbuphine confirmed the formation of nalbuphine.
- Nordiprenorphine (2.Og) was added to a solution of cyclopropanecarboxaldehyde (0.57g) in methanol (16ml) and iV-methylpyrrolidinone (5ml).
- Platinum on carbon catalyst added and mixture hydrogenated at 50°C and 40 psi. After 30 minutes, the catalyst was filtered off and the reaction liquors diluted with chloroform (6ml) and washed with water (20ml). The product was extracted from the aqueous phase with chloroform (3 x 6ml) and the combined organic layer washed with water (5 x 20ml). The solvent was removed under vacuum to yield an off-white solid. HPLC analysis of the residue confirmed that the product was consistent with a reference standard of diprenorphine alkaloid.
- Example 6 Preparation of Buprenorph ⁇ ne from Norbuprenorph ⁇ ne
- Norbuprenorphine (lO.Og, 24.2mmol), cyclopropanecarboxaldehyde (2.2ml, 29.0mmol), iV-methylpyrrolidinone (30ml) and methanol (70ml) were hydrogenated at
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES05782842T ES2322486T5 (en) | 2004-09-30 | 2005-09-14 | Preparation of opioid analgesics by reductive alkylation |
DE602005013986T DE602005013986D1 (en) | 2004-09-30 | 2005-09-14 | PREPARATION OPIATER ANALGETICS BY REDUCING ALKYLATION |
CN2005800326607A CN101027307B (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesics by reductive alkylation |
AT05782842T ATE428715T1 (en) | 2004-09-30 | 2005-09-14 | PRODUCTION OF OPIATER ANALGESICS BY REDUCTIVE ALKYLATION |
DK05782842.8T DK1794165T4 (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesic by reductive alkylation |
US11/628,210 US8119803B2 (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesics by reductive alkylation |
PL05782842T PL1794165T5 (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesics by reductive alkylation |
EP05782842.8A EP1794165B2 (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesics by reductive alkylation |
AU2005288728A AU2005288728B2 (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesics by reductive alkylation |
ZA2007/01784A ZA200701784B (en) | 2004-09-30 | 2007-02-28 | Preparation of opiate analgesics by reductive alkylation |
US13/030,652 US8318937B2 (en) | 2004-09-30 | 2011-02-18 | Preparation of opiate analgesics by reductive alkylation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0421687.5A GB0421687D0 (en) | 2004-09-30 | 2004-09-30 | Preparation of opiate analgesics |
GB0421687.5 | 2004-09-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/628,210 A-371-Of-International US8119803B2 (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesics by reductive alkylation |
US13/030,652 Continuation US8318937B2 (en) | 2004-09-30 | 2011-02-18 | Preparation of opiate analgesics by reductive alkylation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006035195A1 true WO2006035195A1 (en) | 2006-04-06 |
Family
ID=33427785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/003547 WO2006035195A1 (en) | 2004-09-30 | 2005-09-14 | Preparation of opiate analgesics by reductive alkylation |
Country Status (13)
Country | Link |
---|---|
US (2) | US8119803B2 (en) |
EP (1) | EP1794165B2 (en) |
CN (1) | CN101027307B (en) |
AT (1) | ATE428715T1 (en) |
AU (1) | AU2005288728B2 (en) |
DE (1) | DE602005013986D1 (en) |
DK (1) | DK1794165T4 (en) |
ES (1) | ES2322486T5 (en) |
GB (1) | GB0421687D0 (en) |
PL (1) | PL1794165T5 (en) |
PT (1) | PT1794165E (en) |
WO (1) | WO2006035195A1 (en) |
ZA (1) | ZA200701784B (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2438401A (en) * | 2006-05-25 | 2007-11-28 | Alpharma Aps | Preparation of morphinan derivatives comprising N-demethylation, reductive amination and O-demethylation steps |
GB2438399A (en) * | 2006-05-25 | 2007-11-28 | Alpharma Aps | Preparation of N-alkylated morphinans by reduction of an iminium group |
GB2444052A (en) * | 2006-05-25 | 2008-05-28 | Alpharma Aps | Processes of preparing morphinan derivatives such as naltrexone and naloxone comprising O- and N-demethylation and reductive alkylation steps |
WO2009012005A1 (en) | 2007-07-17 | 2009-01-22 | Mallinckrodt Inc. | Preparation of n-alkylated opiates by reductive amination |
EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
WO2010039222A2 (en) * | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | Processes for the selective amination of ketomorphinans |
WO2010096416A1 (en) * | 2009-02-17 | 2010-08-26 | Mallinckrodt Inc. | Process for the reductive alkylation of normorphinans |
WO2011021029A1 (en) | 2009-08-17 | 2011-02-24 | Johnson Matthey Public Limited Company | Process for reducing the 6-keto group of a morphinan alkaloid to the 6-hydroxy group by hydrogenation |
US7985858B2 (en) | 2007-05-04 | 2011-07-26 | Mallinckrodt Inc. | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates |
US8471023B2 (en) | 2009-06-11 | 2013-06-25 | Mallinckrodt Llc | Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer |
US8519133B2 (en) | 2009-06-11 | 2013-08-27 | Mallinckrodt Llc | Preparation of 6-alpha-amino N-substituted morphinans by catalytic hydrogen transfer |
US8624031B2 (en) | 2011-09-08 | 2014-01-07 | Mallinckrodt Llc | Production of alkaloids without the isolation of intermediates |
WO2014033530A1 (en) | 2012-08-27 | 2014-03-06 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
WO2014091297A1 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Spirocyclic morphinans and their use |
WO2014091295A1 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Pyridonemorphinan analogs and biological activity on opioid receptors |
WO2014091298A2 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Nitrogen containing morphinan derivatives and the use thereof |
WO2014102587A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | 7,8-cyclicmorphinan analogs |
WO2014102593A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
WO2014102591A1 (en) | 2012-12-31 | 2014-07-03 | Rhodes Technologies | PROCESS FOR PREPARING 7β-SUBSTITUTED 6α,14α -ETHENOMORPHINANS AND 7β-SUBSTITUTED 6α,14α-ETHANOMORPHINANS |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
WO2015066443A1 (en) | 2013-11-01 | 2015-05-07 | Mallinckrodt Llc | Convenient preparation of n-substituted morphinan-6-ols from morphinan-6-ones |
WO2015097546A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Propellane-based compounds and their use as opioid receptor modulators |
WO2015097548A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
WO2015097547A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
WO2015097545A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
WO2015102682A1 (en) | 2013-12-30 | 2015-07-09 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
US9296699B2 (en) | 2011-06-09 | 2016-03-29 | Mallinckrodt Llc | Reductive amination of 6-keto morphinans by catalytic hydrogen transfer |
WO2018116281A1 (en) | 2016-12-23 | 2018-06-28 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
WO2019165298A1 (en) | 2018-02-23 | 2019-08-29 | Rhodes Technologies | Novel opioid compounds and uses thereof |
US10435406B2 (en) | 2014-12-05 | 2019-10-08 | Purdue Pharma L.P. | 6,7-cyclicmorphinan derivatives and use thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007137785A2 (en) * | 2006-05-25 | 2007-12-06 | Alpharma (Bermuda) Investments Ltd | Process useful in the preparation of morphinan antagonists |
KR100780932B1 (en) * | 2006-05-30 | 2007-11-30 | 엠텍비젼 주식회사 | Color interpolation method and device |
US8962841B2 (en) * | 2007-06-29 | 2015-02-24 | Brock University | Methods for one-pot N-demethylation/N-functionalization of morphine and tropane alkaloids |
EP2344509B1 (en) | 2008-09-30 | 2015-11-11 | Mallinckrodt LLC | Processes for the production of buprenorphine with reduced impurity formation |
US8273887B2 (en) * | 2008-09-30 | 2012-09-25 | Mallinckrodt Llc | Processes for synthesis of opiate alkaloid derivatives |
GB201313915D0 (en) | 2013-08-02 | 2013-09-18 | Johnson Matthey Plc | Process |
WO2015082932A1 (en) | 2013-12-05 | 2015-06-11 | The University Of Bath | Novel opioid compounds and their uses |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3717643A (en) * | 1967-05-04 | 1973-02-20 | Sterling Drug Inc | N-substituted-norapomorphines |
US3793329A (en) * | 1971-02-19 | 1974-02-19 | H Merz | N-(furyl-methyl)-3-oxy-morphinans and salts thereof |
US4082744A (en) * | 1973-05-08 | 1978-04-04 | Nihon Iyakuhin Kogyo Co., Ltd. | 4-benzazonine derivatives and process for preparation thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1136214A (en) | 1965-06-15 | 1968-12-11 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US4190601A (en) † | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
IE52502B1 (en) † | 1981-03-27 | 1987-11-25 | Wyeth John & Brother Ltd | Morpholines |
US5869669A (en) * | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
-
2004
- 2004-09-30 GB GBGB0421687.5A patent/GB0421687D0/en not_active Ceased
-
2005
- 2005-09-14 AT AT05782842T patent/ATE428715T1/en active
- 2005-09-14 CN CN2005800326607A patent/CN101027307B/en active Active
- 2005-09-14 EP EP05782842.8A patent/EP1794165B2/en active Active
- 2005-09-14 WO PCT/GB2005/003547 patent/WO2006035195A1/en active Application Filing
- 2005-09-14 DK DK05782842.8T patent/DK1794165T4/en active
- 2005-09-14 DE DE602005013986T patent/DE602005013986D1/en active Active
- 2005-09-14 PT PT05782842T patent/PT1794165E/en unknown
- 2005-09-14 AU AU2005288728A patent/AU2005288728B2/en active Active
- 2005-09-14 ES ES05782842T patent/ES2322486T5/en active Active
- 2005-09-14 US US11/628,210 patent/US8119803B2/en active Active
- 2005-09-14 PL PL05782842T patent/PL1794165T5/en unknown
-
2007
- 2007-02-28 ZA ZA2007/01784A patent/ZA200701784B/en unknown
-
2011
- 2011-02-18 US US13/030,652 patent/US8318937B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3717643A (en) * | 1967-05-04 | 1973-02-20 | Sterling Drug Inc | N-substituted-norapomorphines |
US3793329A (en) * | 1971-02-19 | 1974-02-19 | H Merz | N-(furyl-methyl)-3-oxy-morphinans and salts thereof |
US4082744A (en) * | 1973-05-08 | 1978-04-04 | Nihon Iyakuhin Kogyo Co., Ltd. | 4-benzazonine derivatives and process for preparation thereof |
Non-Patent Citations (4)
Title |
---|
ATKINSON ARTHUR D ET AL: "Emetic Actvity of N-substituted Norapomorphines", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 18, no. 10, October 1975 (1975-10-01), pages 1000 - 1003, XP002118113, ISSN: 0022-2623 * |
BENTLEY ET AL., J. AMER. CHEM. SOC., vol. 89, 1967, pages 3281 - 92 |
OLOFSON ET AL., TET. LETT., 1977, pages 1567 - 70 |
ORGANIC SYNTHESES, COLLECTIVE, vol. 6, pages 312 |
Cited By (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2471801B (en) * | 2006-05-25 | 2011-02-16 | Alpharma | Process useful in the preparation of morphine antagonists |
GB2438399A (en) * | 2006-05-25 | 2007-11-28 | Alpharma Aps | Preparation of N-alkylated morphinans by reduction of an iminium group |
GB2444052A (en) * | 2006-05-25 | 2008-05-28 | Alpharma Aps | Processes of preparing morphinan derivatives such as naltrexone and naloxone comprising O- and N-demethylation and reductive alkylation steps |
GB2438401A (en) * | 2006-05-25 | 2007-11-28 | Alpharma Aps | Preparation of morphinan derivatives comprising N-demethylation, reductive amination and O-demethylation steps |
GB2471800B (en) * | 2006-05-25 | 2011-03-09 | Alpharma | Preparation of N-alkylated morphinans by reduction of an iminium group |
GB2471803B (en) * | 2006-05-25 | 2011-02-16 | Alpharma | Chemical process |
GB2471801A (en) * | 2006-05-25 | 2011-01-12 | Alpharma | Preparation of morphinan derivatives comprising N-demethylation, reductive amination and O-demethylation steps |
GB2471803A (en) * | 2006-05-25 | 2011-01-12 | Alpharma | Processes of preparing morphinan derivatives such as naltrexone and naloxone comprising O- and N-demethylation and reductive alkylation steps |
GB2471800A (en) * | 2006-05-25 | 2011-01-12 | Alpharma | Preparation of N-alkylated morphinans by reduction of an iminium group |
US8524904B2 (en) | 2007-05-04 | 2013-09-03 | Mallinckrodt Llc | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates |
US8273888B2 (en) | 2007-05-04 | 2012-09-25 | Mallinckrodt Llc | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates |
AU2010200188B2 (en) * | 2007-05-04 | 2012-02-02 | SpecGx LLC | Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates |
US7985858B2 (en) | 2007-05-04 | 2011-07-26 | Mallinckrodt Inc. | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates |
JP2010533719A (en) * | 2007-07-17 | 2010-10-28 | マリンクロッド・インコーポレイテッド | Preparation of N-alkylated opiates by reductive amination |
WO2009012005A1 (en) | 2007-07-17 | 2009-01-22 | Mallinckrodt Inc. | Preparation of n-alkylated opiates by reductive amination |
US8729266B2 (en) * | 2007-07-17 | 2014-05-20 | Mallinckrodt Llc | Preparation of N-alkylated opiates by reductive amination |
AU2008276385B2 (en) * | 2007-07-17 | 2013-07-18 | SpecGx LLC | Preparation of N-alkylated opiates by reductive amination |
US20100197921A1 (en) * | 2007-07-17 | 2010-08-05 | Grote Christopher W | Preparation of N-Alkylated Opiates by Reductive Amination |
EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
US8269006B2 (en) | 2008-09-30 | 2012-09-18 | Mallinckrodt Llc | Processes for the selective amination of ketomorphinans |
WO2010039222A2 (en) * | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | Processes for the selective amination of ketomorphinans |
WO2010039222A3 (en) * | 2008-09-30 | 2010-11-18 | Mallinckrodt Inc. | Processes for the selective amination of ketomorphinans |
AU2009300392B2 (en) * | 2008-09-30 | 2014-10-23 | SpecGx LLC | Processes for the selective amination of ketomorphinans |
JP2012518013A (en) * | 2009-02-17 | 2012-08-09 | マリンクロッド インコーポレイテッド | Process for reductive alkylation of normorphinan |
WO2010096416A1 (en) * | 2009-02-17 | 2010-08-26 | Mallinckrodt Inc. | Process for the reductive alkylation of normorphinans |
AU2010216150B2 (en) * | 2009-02-17 | 2015-05-14 | Mallinckrodt Llc | Process for the reductive alkylation of normorphinans |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
US8471023B2 (en) | 2009-06-11 | 2013-06-25 | Mallinckrodt Llc | Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer |
US8519133B2 (en) | 2009-06-11 | 2013-08-27 | Mallinckrodt Llc | Preparation of 6-alpha-amino N-substituted morphinans by catalytic hydrogen transfer |
US8853402B2 (en) | 2009-08-17 | 2014-10-07 | Johnson Matthey Public Limited Company | Process for reducing the 6-keto group of a morphinan alkaloid to the 6-hydroxy group by hydrogenation |
WO2011021029A1 (en) | 2009-08-17 | 2011-02-24 | Johnson Matthey Public Limited Company | Process for reducing the 6-keto group of a morphinan alkaloid to the 6-hydroxy group by hydrogenation |
US9296699B2 (en) | 2011-06-09 | 2016-03-29 | Mallinckrodt Llc | Reductive amination of 6-keto morphinans by catalytic hydrogen transfer |
US8624031B2 (en) | 2011-09-08 | 2014-01-07 | Mallinckrodt Llc | Production of alkaloids without the isolation of intermediates |
US9315514B2 (en) | 2012-08-27 | 2016-04-19 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
WO2014033530A1 (en) | 2012-08-27 | 2014-03-06 | Rhodes Technologies | 1,3-dioxanomorphides and 1,3-dioxanocodides |
US9273048B2 (en) | 2012-12-14 | 2016-03-01 | Purdue Pharma L.P. | Spirocyclic morphinans and their use |
US8987287B2 (en) | 2012-12-14 | 2015-03-24 | Purdue Pharma L.P. | Spirocyclic morphinans and their use |
US8937084B2 (en) | 2012-12-14 | 2015-01-20 | Purdue Pharma L.P. | Nitrogen containing morphinan derivatives and the use thereof |
WO2014091297A1 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Spirocyclic morphinans and their use |
US9403824B2 (en) | 2012-12-14 | 2016-08-02 | Purdue Pharma L.P. | Pyridonemorphinan analogs and biological activity on opioid receptors |
WO2014091298A2 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Nitrogen containing morphinan derivatives and the use thereof |
US8980906B2 (en) | 2012-12-14 | 2015-03-17 | Purdue Pharma L.P. | Pyridonemorphinan analogs and biological activity on opioid receptors |
WO2014091295A1 (en) | 2012-12-14 | 2014-06-19 | Purdue Pharma L.P. | Pyridonemorphinan analogs and biological activity on opioid receptors |
WO2014102593A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
US9388162B2 (en) | 2012-12-28 | 2016-07-12 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
WO2014102587A1 (en) | 2012-12-28 | 2014-07-03 | Purdue Pharma L.P. | 7,8-cyclicmorphinan analogs |
US8957084B2 (en) | 2012-12-28 | 2015-02-17 | Purdue Pharma L.P. | 7,8-cyclicmorphinan analogs |
US8946255B2 (en) | 2012-12-28 | 2015-02-03 | Purdue Pharma L.P. | Substituted morphinans and the use thereof |
US9834562B2 (en) | 2012-12-31 | 2017-12-05 | Rhodes Technologies | 7 beta-substituted 6a, 14a-ethenomorphinans and 7beta-substituted 6a, 14a-ethanomorphinans |
WO2014102591A1 (en) | 2012-12-31 | 2014-07-03 | Rhodes Technologies | PROCESS FOR PREPARING 7β-SUBSTITUTED 6α,14α -ETHENOMORPHINANS AND 7β-SUBSTITUTED 6α,14α-ETHANOMORPHINANS |
WO2015066443A1 (en) | 2013-11-01 | 2015-05-07 | Mallinckrodt Llc | Convenient preparation of n-substituted morphinan-6-ols from morphinan-6-ones |
EP3063152B1 (en) * | 2013-11-01 | 2019-08-07 | SpecGx LLC | Convenient preparation of n-substituted morphinan-6-ols from morphinan-6-ones |
US9499556B2 (en) | 2013-11-01 | 2016-11-22 | Mallinckrodt Llc | Convenient preparation of N-substituted morphinan-6-ols from morphinan-6-ones |
US9340542B2 (en) | 2013-12-26 | 2016-05-17 | Purdue Pharma L.P. | Propellane-based compounds and the use thereof |
WO2015097548A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
US9994571B2 (en) | 2013-12-26 | 2018-06-12 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
WO2015097546A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Propellane-based compounds and their use as opioid receptor modulators |
WO2015097547A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | 10-substituted morphinan hydantoins |
US9862726B2 (en) | 2013-12-26 | 2018-01-09 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
US9988392B2 (en) | 2013-12-26 | 2018-06-05 | Purdue Pharma L.P. | 7-beta-alkyl analogs of orvinols |
WO2015097545A1 (en) | 2013-12-26 | 2015-07-02 | Purdue Pharma L.P. | Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans |
WO2015102682A1 (en) | 2013-12-30 | 2015-07-09 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
US10435406B2 (en) | 2014-12-05 | 2019-10-08 | Purdue Pharma L.P. | 6,7-cyclicmorphinan derivatives and use thereof |
WO2018116281A1 (en) | 2016-12-23 | 2018-06-28 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
US11124505B2 (en) | 2016-12-23 | 2021-09-21 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof |
US11731963B2 (en) | 2016-12-23 | 2023-08-22 | Minoryx Therapeutics S.L. | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof |
WO2019165298A1 (en) | 2018-02-23 | 2019-08-29 | Rhodes Technologies | Novel opioid compounds and uses thereof |
US11845759B2 (en) | 2018-02-23 | 2023-12-19 | Rhodes Technologies | Opioid compounds and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
ATE428715T1 (en) | 2009-05-15 |
EP1794165A1 (en) | 2007-06-13 |
GB0421687D0 (en) | 2004-11-03 |
DE602005013986D1 (en) | 2009-05-28 |
DK1794165T4 (en) | 2020-07-13 |
US8318937B2 (en) | 2012-11-27 |
AU2005288728B2 (en) | 2012-05-03 |
EP1794165B2 (en) | 2020-04-29 |
CN101027307B (en) | 2011-12-21 |
ZA200701784B (en) | 2008-11-26 |
ES2322486T5 (en) | 2021-02-05 |
PL1794165T5 (en) | 2020-11-16 |
US8119803B2 (en) | 2012-02-21 |
AU2005288728A1 (en) | 2006-04-06 |
CN101027307A (en) | 2007-08-29 |
PL1794165T3 (en) | 2009-09-30 |
PT1794165E (en) | 2009-05-06 |
US20080045715A1 (en) | 2008-02-21 |
ES2322486T3 (en) | 2009-06-22 |
EP1794165B1 (en) | 2009-04-15 |
DK1794165T3 (en) | 2010-03-08 |
US20120046466A9 (en) | 2012-02-23 |
US20110144341A1 (en) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1794165B2 (en) | Preparation of opiate analgesics by reductive alkylation | |
TWI471289B (en) | Process for n-dealkylation of tertiary amines | |
AU2007267362B2 (en) | Process useful in the preparation of morphinan antagonists | |
EP1981891B1 (en) | The use of oripavine as a starting material for buprenorphine | |
US8227609B2 (en) | Process for purifying noroxymorphone compounds | |
EP2222643B1 (en) | Sinomenine derivatives and processes for their synthesis | |
US9499557B2 (en) | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | |
JP2007505935A (en) | Synthetic methods of morphinan compounds and intermediates thereof | |
EP2480555B1 (en) | Methods for producing hydrocodone, hydromorphone or a derivative thereof | |
GB2438401A (en) | Preparation of morphinan derivatives comprising N-demethylation, reductive amination and O-demethylation steps | |
GB2444052A (en) | Processes of preparing morphinan derivatives such as naltrexone and naloxone comprising O- and N-demethylation and reductive alkylation steps | |
GB2438399A (en) | Preparation of N-alkylated morphinans by reduction of an iminium group |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005782842 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005288728 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005288728 Country of ref document: AU Date of ref document: 20050914 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005288728 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580032660.7 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005782842 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11628210 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11628210 Country of ref document: US |